Research Highlight | Published:

HAEMATOLOGICAL CANCER

New first-line options in CLL

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Fischer, K. et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N. Engl. J. Med. 380, 2225–2236 (2019)

    2. Jain, N. et al. Ibrutinib and venetoclax for first-line treatment of CLL. N. Engl. J. Med. 380, 2095–2103 (2019)

    Download references

    Author information

    Correspondence to Diana Romero.

    Rights and permissions

    Reprints and Permissions

    About this article